Objective: De®ciencies of essential fatty acids (EFA), vitamin A (retinol) and vitamin E (a-and g-tocopherol) were studied in non-HPN patients with different degrees of fat malabsorption (managing without home parenteral nutrition (HPN)), and in HPN-patients receiving HPN with and without parenteral lipids. Design and subjects: Phospholipid fatty acids (including EFA), cholesterol, retinol, a-and g-tocopherol in plasma and the intestinal absorption of fatty acids and energy (balance-studies) were measured in 40 non-HPN patients, 44 HPN patients and 35 controls. Subgroups were non-HPN patients with fat:total energy absorption ratios b25% (A), between 15 and 25% (B), and`15% (C), and HPN patients receiving (D) and not receiving parenteral lipids (E). Results: Intestinal absorption of the EFA linoleic acid was 8.2, 4.4, 3.8, 0.5 and 0.5 gaday and corresponding plasma concentrations were 17.3%, 15.5%, 13.1%, 12.1% and 8.9% in groups A ± E, respectively (P`0.001). De®ciencies in EFA, de®ned as a Holman index b0.2 (20:3n-9a20:4n-6 ratio), were con®ned to 42% of the patients in group E. Plasma cholesterol was decreased in groups B ± E. Plasma retinol was reduced (below the lower 2.5% con®dence interval of controls) in 7% of non-HPN patients and in 20% of HPN patients. Plasma a-tocopherol was reduced in 64% of patients from groups B ± E. Plasma g-tocopherol was decreased in 33% of the patients, except in HPN-patients receiving parenteral lipids. Conclusions: Plasma linoleic acid may decrease considerably (from 26% to 8 ± 10%) as fat absorption decreases before secondary signs of essential fatty acid de®ciencies occur (an increase in 20:3n-9 and the Holman index). In this study this was con®ned to patients on lipid-free HPN. Vitamin A de®ciencies were mainly seen in HPN patients. Vitamin E de®ciencies were common in both HPN and non-HPN patients, but administration of parenteral lipids normalized plasma g-tocopherol. Sponsorship: The study was sponsored by Rigshospitalet.
Introduction
Suf®cient intake and absorption of a diet is required to meet or exceed the nutritional needs of the individual, thereby maintaining the nutritional equilibrium, body composition, function and health (Jeejeebhoy et al, 1990a) . This equilibrium is challenged in patients with diseases that impair the integrity of the intestinal epithelium, either through in¯am-mation, in®ltration, surgical resection or ischemia, causing malabsorption. Short bowel patients frequently compensate for the malabsorption by hyperphagia (Cosnes et al, 1985 (Cosnes et al, , 1990 DiCecco et al, 1987) , but patients who do not meet their nutritional needs suffer from intestinal failure, imposing the need for parenteral support (Fleming & Remington, 1981) .
De®ciencies may evolve in the intermediate phase from moderate malabsorption to the condition of intestinal failure according to the balance between the dietary intake and the pre-existent body stores on one side, and the metabolic needs and losses in stools and urine the on the other. Some de®ciencies may have long latency periods before becoming clinically manifest, whereas others such as electrolyte depletion and dehydration may evolve rapidly and necessitate parenteral support.
In short bowel patients the malabsorption of fat is more predominant than the malabsorption of carbohydrate and protein (Messing et al, 1991) . This is most pronounced in short bowel patients with a preserved colon, where carbohydrate and protein malabsorbed in the small bowel are fermented in the colon, thus salvaging energy through the absorption of short chain fatty acids (Nordgaard et al, 1994 (Nordgaard et al, , 1996 . Therefore the energy contribution from fat absorption in relation to the total energy absorption may decrease with an increase in the overall energy malabsorption. Accordingly, the patients who manage in a situation with severe malabsorption without parenteral support by a compensatory hyperphagia may cover a low percentage of their total energy requirements with energy supplied from fat absorption. The reduced absorption of fat, and the concurrent reduced absorption of essential fatty acids (EFAs) and fat-soluble vitamins, may lead to depleted body stores or localized tissue de®ciencies and ultimately clinical signs of de®ciency of EFAs and fat-soluble vitamins A, D, E and K. In these patients the occurrence of subclinical or clinical de®ciencies may evolve more insidiously and receive less attention than in the patients who receive parenteral support, in whom attention is addressed to the maintenance of the nutritional equilibrium through the parenteral supplementation of fat and fatsoluble vitamins.
In this study the ratio between the energy absorption from fat and the total energy absorption was measured in balance studies in patients with severe malabsorption and related secondary biochemical signs of a reduced fat absorption by measurement of fatty acid composition of plasma phospholipids, plasma cholesterol (total cholesterol high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol), plasma vitamin A (retinol) and plasma vitamin E (a-and g-tocopherols). One group of patients with functional or anatomical short bowel syndrome managed without home parenteral nutrition (non-HPN patients), whereas the other group of patients had intestinal failure and received HPN (HPN patients).
Methods

Patients and control subjects
The two groups of patients were recruited by mail for the study. Both groups had continuity of care in the program of intestinal insuf®ciency and failure at Rigshospitalet, Copenhagen. One group consisted of 76 non-HPN patients with intestinal insuf®ciency, de®ned as either a faecal energy excretion of more than 2.0 MJaday (measured at a previous admission), or a remnant small intestine measured intraoperatively from the ligament of Treitz of 200 cm or less, or consecutive small intestinal resections exceeding 150 cm. The other group consisted of the 58 patients with intestinal failure, corresponding to approximately 75% of patients receiving HPN in Denmark (Jeppesen et al, 1998a) , who received or initiated HPN in the period from the beginning of the study in November 1995 until the end in March 1997. Forty-®ve of the 76 non-HPN patients with intestinal insuf®ciency and 46 of the 58 HPN patients were willing to participate in the study. These patients were representative of the total regarding employment status. One of the non-HPN patients was excluded from the study, as she experienced a gastroenteritis and vomiting during admission. One HPN patient with a protein-losing enteropathy was excluded from the study, as she only used her catheter for intravenous calcium supplements. Five HPN patients had to be excluded from the study because the appropriate blood tests for vitamin and fatty acid analysis were not taken. Forty-four non-HPN and 40 HPN patients remained for investigation.
Intestinal transit was measured as the time from oral administration of a brilliant blue marker to its appearance in the faeces in non-HPN patients and HPN patients with a preserved colon prior to inclusion in the study. Only three of these patients had a transit time of more than 10 h. In our laboratory the reference interval of the intestinal transit time measured by the brilliant blue test in normal subjects has been established to be between 10 and 36 h.
Parenteral nutrition and¯uids
All HPN patients had parenteral supplements of nutrients or saline at least three times a week. The composition and energy content in parenteral supplements was calculated from information given by the manufacturers. Energy and electrolyte supplements were adjusted to maintain a normal body weight, hydration, urine output and normal levels of plasma albumin and plasma electrolytes. Glucose was supplied as glucose potassium phosphate 27% (The Counties Medicine Registrations Of®ce in Denmark, Copenhagen) or glucose 5, 10, 20 or 50%. Patients were supplied with synthetic amino acids (Vamin 14 or Vamin glucose, Pharmacia, Copenhagen). Electrolytes were given as a hypertonic electrolyte solution containing calcium, potassium, sodium, magnesium, zinc, copper, acetate, chloride, iodide and glucose. Attempts were made to use`standard' solutions if at all possible (1 l of glucose 27% potassium phosphate, 1 l of Vamin 14, 1 l of electrolytes daily), but the composition of the HPN solution was often adjusted to meet the patient's individual requirement. The rhythm of administration was generally cyclic nocturnal, but four patients with large stoma volumes had supplements of saline during daytime. The recommended infusion time of standard 3 l HPN bags was 10 h. Lipids (10 or 20% Intralipid, Pharmacia, Copenhagen) were supplied in separate 500 ml bottles once or twice a week, mainly to patients with large energy demands or poor nutritional status in whom energy requirements were not met by the energy content of the standard 3 l bags (6.8 MJ). Sixteen of the 40 HPN patients included in this study received parenteral lipids. Fat-soluble vitamins (Vitalipid Adult, Pharmacia, Copenhagen) were added to the parenteral lipid emulsions in 12 of the 16 HPN patients or given once a week as a 10 ml bolus dose in 16 of the 24 HPN patients not receiving parenteral lipids. Thus, lipid infusion and supplements of fat-soluble vitamins is not obligatory in the Danish home parenteral nutrition regime, but is based on a clinical evaluation of the need. Therefore, the exclusion of lipids and vitamins in some patients was not due to intolerance or adverse effects. None of the patients in this study suffered from clinical signs of EFAD, vitamin A or E de®ciency.
Study protocol
Prior to admission the patients were contacted by phone and informed about the exact study-procedures. Patients were instructed to bring special food items in duplicate (snacks, candy, soft drinks etc;), if they had dietary requests that could not be provided for by the hospital. The patients were admitted for 2 1 2 days. At arrival the ®rst afternoon the patients were given three containers and an electronic precision balance. Two of the containers were for collection of faeces and urine, respectively. In the third container the patients were told to collect a duplicate of their oral intake Ð beverages and diet. Using the precision balance, which had a scale in grams, the patients were instructed to weigh out individual food items and beverages separately; a portion for themselves and an equal portion for the container. The patients were instructed that they could eat just as they pleased from a continental style breakfast, lunch and supper buffet, each containing a wide range of food items. Beverages included water, tea, coffee, milkproducts, soft-drinks, juice, glucose-saline solutions etc. Sandwiches, biscuits and beverages were available in the kitchen between meals, and patients were allowed to use De®ciencies related to fat malabsorption PB Jeppesen et al the hospital cafeteria, as long as double portions of the diet were collected.
The patients were told to abstain from food intake from 10 pm to 8 am during the day of admission. This was done in order to avoid some of the faecal excretion during the ®rst 24 h of study being a re¯ection of the intake prior to the balance period. The study-and collection-period began at 8 a.m. on the second day of admission, where fasting blood test were taken and patients were requested to urinate, defecate or empty their stoma-bags. During the next 48 h the patients collected the faeces, urine and the duplicate diet in the three containers. The restriction on the diet intake from 10 pm the last night of admission ensured a complete collection of the faeces derived from diet intake during the previous 48 h balance period. The faeces were collected on ice and immediately frozen at 720 C until the analyses.
The patients were interviewed regarding composition and volume of their parenteral support. The patients had their usual parenteral supplements and medication during admission. The height and the fasting body weight of the patients were measured during admission. Fasting whole blood samples (10 ml) for fatty acid, lipoprotein and vitamin analyses were collected in EDTA. Patients receiving parenteral lipids and vitamins were instructed not to take these 48 h before the blood test.
The protocol was approved by the Ethics Committee for Medical Research in Copenhagen, Denmark. Procedures followed were in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 1983. All participants signed informed consent before beginning the study.
Dietary and faecal analyses
Analyses of the diet and faeces were done on homogenized and freeze-dried samples. The dietary and faecal energy content was determined by bomb calorimetry with approximately 1 g of freeze-dried samples ignited in an IKA adiabatic calorimeter, model C 4000 A (IKA-Analysentechnik, Heitersheim, Germany). The dietary and faecal fatty acids were determined by combined gas ± liquid chromatography and mass spectrometry as previously described (Jeppesen et al, 1998b) . In general the peaks were identi®ed from their retention time. However, in some instances, especially in the faeces of patients with a preserved colon, positive identi®cation of the fatty acid peaks was based on mass spectrometry. The energy conversion factor for fatty acids was 39.1 kJag. The intestinal energy and fat absorptions were calculated as the difference between the ingested and excreted energy and fat.
Basis of the calculation of parenteral supplements
In general the content of the parenteral nutrition was calculated from information given by the manufacturers of the products. Intralipid 10% and 20% contained 52% linoleic acid and 8% linolenic acid. The triglyceride content was 115 and 230 mmolal, respectively. Trilineoleat content was 52.6 and 105.2 gal, whereas trilinolenat content was 8.0 and 16.1 gal. Energy contents in the two emulsions were 4600 and 8400 kJal, respectively. Information regarding the content of fat-soluble vitamins in the Intralipid solutions could not be provided by the manufacturer. However, studies by Kelly et al (1989) determined the a, b g, and d-tocopherol isomer concentrations in the Intralipid emulsion to 12.0, 91.0 and 43.2 mgal, respectively, and these values were used for the estimate of parenteral vitamin E supply in this study. Thus, the majority of vitamin E present in Intralipid was as the b, g and dtocopherol isomers with a-tocopherol representing only about 8% of the total vitamin E concentration. The relative potencies of the tocopherols have been estimated to be 1.0, 0.2 and 0.01 for a, b g and d-tocopherol, respectively. Therefore the plasma total a-tocopherol equivalent may be calculated as a-tocopherol 0.2 g-toco-pherol 0.01d-tocopherol (Century & Horwitt, 1965) . d-Tocopherol was not measured in this study and the plasma total a-tocopherol equivalent was calculated as a-tocopherol 0.2 gtocopherol. The retinol and a-tocopherol content of the 10 ml vitamin supply was 990 mg and 9.1 mg, respectively, based on information from the manufacturer.
Plasma essential fatty acid analysis Fatty acid analysis was performed as described earlier (Jeppesen et al, 1997) . The total lipid fraction from plasma samples was extracted according to the method of Folch et al (1956) . The phospholipid fraction was isolated by thin layer chromatography and saponi®ed and methylated using BF 3 (Morrison & Smith, 1964) . The fatty acid methyl esters were analysed by gas ± liquid chromatography using a Hewlett-Packard 5890, series II, chromatograph equipped with a fused silica column (SP2380, 60 m60.25 mm i.d., Supelco Inc., Bellefonte, PA).
Cholesterol in plasma lipoproteins
Cholesterol, HDL cholesterol and triglycerides were measured by enzymatic colorimetric tests (cholesterol CHOD-PAP-method 1 491 458, HDL cholesterol precipitation reagent 543 004, and triglycerides GPO-PAP 1 730 711, respectively, Boehringer Mannheim Systems, Ingelheim am Rhein, Germany; Burstein et al, 1970) . LDL cholesterol was calculated from the equation, LDL cholesterol total cholesterol 7 (triglyceridesa2.2) 7 HDL cholesterol.
Analysis of fat-soluble vitamins A and E Vitamin A and E were analysed as described by Kaplan et al (1990) . All operations were performed in darkness. Plasma samples were added a-tocopherol acetate as internal standard prior to extraction twice with hexane. Following evaporation of solvent the residue was redissolved in acetonitrilachloroform, 80a20, ®ltered, and transferred to coloured vials. HPLC was performed on a Supelcosil LC-18 column (25 cm64.6 mm, 5 mm, Supelco, Bellefonte, PA, USA) using a¯ow-rate of 2 mlamin, detection at 292 nm and a mobile phase of acetonitrila chloroformaisopropanolawater, 780a160a35a25.
Statistics
Non-parametric testing was performed as observations were not sampled from a population with a normal distribution, and the assumptions of equal variances for a parametric test between groups were not met. Differences between groups were assessed by non-parametric Kruskal ± Wallis one-way ANOVA on ranks. A Tukey's test adjusting for multiple comparisons was used as the post hoc test for multiple pairwise comparisons, and the subscripts a, b, c and d given in tables denote signi®cant differences (Pvalues`0.05) among groups. Calculations were performed using the Sigmastat statistical program package (Jandel Corp, Erkrath, Germany).
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Results
Patient characteristics
The non-HPN patients were divided into three groups according to their energy absorption from fat absorption in relation to their total energy absorption: group A, b25%; group B, 15 ± 25%; and group C`15%, respectively. The HPN patients were divided into those who received parenteral lipids and those who did not: group D, i.v. lipids; and group E, 7 i.v. lipids, respectively (Table 1) . The blood tests of the patients were compared with those of 35 control subjects (laboratory and staff members). Characteristics of the patients and the controls are shown in Table 1 . The median age of the control subjects was lower than in patients in groups B, C and E, respectively. The majority of patients in all groups had Crohn's disease, but none of the patients with in¯ammatory bowel disease had evidence of active disease at the time of the study.
Diet and intestinal absorption
The dietary intake and intestinal absorption of energy, fat and essential fatty acids in the ®ve groups of patients is shown in Table 2 . The non-HPN patients in group C had the largest compensatory hyperphagia compared with the patients in the rest of the groups, and the HPN patients in group D consumed less than the non-HPN patients. The energy absorption was higher in the non-HPN patients compared to the HPN patients, and the energy absorption as percentage of intake was higher in the non-HPN patients in group A compared with HPN patients. The diet fat intake was higher in the non-HPN patients compared with the HPN patients in group D. The fat absorption was higher in the non-HPN patients in groups A and B compared with the HPN patients and the non-HPN patients in group C. The fat absorption in the non-HPN patients in group A was higher compared with non-HPN patients in group B. The fat absorption as a percentage of intake was higher in the non-HPN patients in group A Results are expressed as median with 25% and 75% percentiles given in parentheses. FAaTEA fat absorptionatotal Energy absorption (%). Total energy supply corresponds to the sum of the intestinal energy absorption and the parenteral energy supply. CD Crohn's disease; MT mesenteric thrombosis; Surg complications to surgery; RA radiation enteritis; ID intestinal dysmotility. *Kruskal ± Wallis one-way Anova on ranks. The superscripts a ± d denote statistical difference, P`0.05, by all pairwise multiple comparison procedures (Tukey's test) for multiple comparisons. Results are expressed as median with 25% and 75% percentiles given in parentheses. FAaTEA fat absorptionatotal energy absorption (%). Total energy supply corresponds to the sum of the intestinal energy absorption and the parenteral energy supply. *Kruskal ± Wallis one-way Anova on ranks. The superscripts a ± d denote statistical difference, P`0.05, by all pairwise multiple comparison procedures (Tukey's test) for multiple comparisons.
De®ciencies related to fat malabsorption PB Jeppesen et al compared with the HPN patients and the non-HPN patients in group C. The linoleic acid (18:2n-6) intake was higher in non-HPN patients in group A compared with the HPN patients. The absorption of linoleic acid was higher in the non-HPN patients in groups A and B compared with the HPN patients. The absorption of linoleic acid in the non-HPN patients in group A was higher compared with non-HPN patients in group B.
When calculating the energy absorption from linoleic acid in relation to the total energy supply the median (25 ± 75%) values in groups A ± E were 3.7% (2.9 ± 4.3%), 2.1% (1.5 ± 4.1%), 1.6% (0.8 ± 2.1%), 0.2% (70.2 ± 0.7%), and 0.3% (70.2 ± 0.8%). Thus, the energy absorption from linoleic acid in relation to the total energy supply was higher in the non-HPN patients in group A compared with the HPN patients. The absorption of linoleic acid as a percentage of intake was higher in the non-HPN patients in groups A and B compared with the HPN patients in group D. The absorption of linoleic acid as a percentage of intake was higher in the non-HPN patients in group A compared with non-HPN patients in group B.
Diet linolenic acid (18:3n-3) intake was higher in the non-HPN patients compared with the HPN patients. The linolenic acid absorption was higher in the non-HPN patients in groups A and B compared with the HPN patients. The linolenic acid absorption was higher in the non-HPN patients in group A compared with the patients in group C.
When calculating the energy absorption from linolenic acid in relation to the total energy supply the median (25 ± 75%) values in groups A ± E were 0.6% (0.4 ± 0.7%), 0.5% (0.2 ± 0.7%), 0.2% (0.1 ± 0.3%), 0.0% ( 7 0.1 ± 0.0%), and 0.0% ( 7 0.2 ± 0.1%). Thus, the energy absorption from linolenic acid in relation to the total energy supply was higher in the non-HPN patients in groups A and B compared with the HPN patients and the non-HPN patients in group C. The absorption of linolenic acid in percentage of intake was higher in the non-HPN patients in groups A and B compared with the HPN patients.
Parenteral support of energy, fat, essential fatty acids, retinol and tocopherol The parenteral support to the two groups of patients receiving HPN is given in Table 3 . The need for parenteral energy was signi®cantly higher in patients in group D who received parenteral lipids. These patients received a median of 7.5 and 1.15 gaday of linoleic and linolenic acids, respectively, as a part of the parenteral lipid support. Thus, the parenteral lipids given to HPN patients in group D provided these patients with the same amount of the essential fatty acids, linoleic and linolenic acids, as the non-HPN patients in group A, absorbed by the enteral route. The parenteral supply from lipids and fat-soluble vitamins led to a signi®cantly larger supply of retinol, and a-and g-tocopherol to HPN patients in group D compared with the HPN patients in group E.
Fatty acid composition of plasma phospholipids
The fatty acid composition of plasma phospholipids is given in Table 4 . A progressive decline in the level of linoleic acid (18:2n-6) over the groups 0 and A ± E could be demonstrated. The level of linoleic acid was 21.8% in the control subjects, 17.3%, 15.5%, 13.1%, 12.1%, and 8.9% in patients in groups A ± E, respectively. The level of linolenic acid (18:3n-3) was signi®cantly lower in the HPN patients compared with the non-HPN patients and the controls. The level of linoleic acid (18:2n-6) in the plasma phospholipids correlated positively with the intestinal absorption of linoleic acid in the non-HPN patients and in the HPN not receiving parenteral lipids, as evidenced in Figure 1 . Thus, a low absorption of linoleic acid was re¯ected in a low level of linoleic acid in the plasma phospholipids.
The relation between the level of selected fatty acids and the concentration of linoleic acid in plasma phospholipids is given in Figure 2 . A characteristic sign of essential fatty acid de®ciency (EFAD) is the increase in the level of 20:3n-9 (eicosatrienoic acid), the numerator of the Holman (20:3n-9a20:4n-6) index (Holman et al, 1979) . The level of this fatty acid was 16-fold higher in the HPN patients not receiving parenteral lipids (group E) compared with the level in the control subjects (1.6% compared with 0.1%, P`0.001, Table 4 ). Ten of the 24 HPN patients in group E had a Holman index above 0.2, the classically used biochemical evidence of EFAD, whereas none of the patients in the other groups had EFAD based on this de®nition. Figure 2A illustrates the relation between the level of 20:3n-9 and 18:2n-6 in the plasma phospholipids in the non-HPN and HPN patients, respectively. In the non-HPN patients the maximum elevation of 20:3n-9 was to a concentration of 0.3% in spite of levels of 18:2n-6 ranging from 9.4% to 26.0%. In the HPN patients all patients with an 18:2n-6 level above 10% had a 20:3n-9 level below 1.1%. All eight HPN patients with a level of 18:2n-6 below 8% had elevated 20:3n-9 above 1.8% (range 1.8 ± 6.3%). Seven of the eight patients did not receive parenteral lipids. In the 10 HPN patients with 18:2n-6 between 8 and 10% the 20:3n-9 level ranged from 0.6 to 3.6%. Eight of the 10 patients did not receive parenteral lipids. Figure 2B illustrates that no clear relation existed between 18:2n-6 and the denominator of the Holman index, 20:4n-6 (arachidonic acid). Similar ®ndings were evident for the other members of the n-6 family (ie 18:3n-6, 20:3n-6, 22:4n-6 and 22:6n-6, not shown) and the members of the n-3 family given in Table 4 (ie 18:3n-3, 20:5n-3, 22:5n-3 and 22:6n-3, not shown). Figure 2C illustrates the compen- Results are expressed as median with 25% and 75% percentiles given in parentheses. *Mann ± Whitney rank sum test.
De®ciencies related to fat malabsorption PB Jeppesen et al satory increase in 16:1n-7 with a decrease in the level of 18:2n-6. A similar relation existed for 18:1n-7 and 18:1n-9, respectively (not shown), and these compensatory changes were demonstrated in both the HPN and the non-HPN patients. A similar relation between 18:2n-6 and 20:1n-9 ( Figure 2D ) or 18:2n-6 and 16:1n-9 (not shown) could not be demonstrated. Comparing the responsiveness or sensitivity of various indicators of EFAD, Figure 3 illustrates the relation between the Holman index (20:3n-9a20:4n-6 ratio), 20:3n-9, 20:3n-9a18:2n-6, and n-9 n-7an-6 n-3 plotted according to an arbitrary range of 0 ± 1.00, where 0 represents the patient with the lowest value, 1.00 the patient with the highest value, and the patients in between according to their proportional value.
Cholesterol in plasma lipoproteins
The cholesterol content of the plasma lipoproteins is given in Table 5 . Total cholesterol was lower in groups B ± E compared with the control subjects. A trend of a parallel reduction in both HDL and LDL cholesterol in the HPN patients made the HDLatotal cholesterol ratio unchanged compared the control subjects, whereas an increase in the 12.1 (11.2 ± 12.6) a 11.8 (11.0 ± 12.4) ab 12.8 (12.0 ± 13.7) ab 13.9 (11.9 ± 15.6) bc 12.7 (11.8 ± 14.2) ab 15.1 (13.6 ± 19. 3) a`0 .001 22:6 n-3 3.0 (2.5 ± 3.5) 3.1 (2.7 ± 3.8) 2.9 (2.6 ± 3.7) 2.6 (2.1 ± 3.3) 2.6 (2.0 ± 2.9) 2.6 (2.1 ± 3.1) 0.06 Total n-3 FA 4.6 (4.2 ± 5.6) 
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HDLatotal cholesterol ratio was observed in the non-HPN patients.
Plasma fat-soluble vitamins A and E
The concentration of the fat-soluble vitamins A and E is given in Table 6 . No differences in the plasma retinol concentration could be demonstrated among the groups. The lower limit of the 2.5 ± 97.5% con®dence interval of the retinol concentration in the control subjects was 0.52 mgaml (range, 0.50 ± 2.29 mgaml). Eight of 11 patients (73%) with a retinol concentration below 0.52 mgaml were among those who received HPN. Only two of these patients did not receive parenteral vitamin A supplements. Plasma a-tocopherol concentration was signi®cantly lower in the non-HPN patients in groups B and C and in the HPN patients group D and E compared with the control subjects ( Table 6 ). The lower limit of the 2.5 ± 97.5% con®dence interval of the plasma a-tocopherol concentration in the control subjects was 4.25 mgaml (range, 4.18 ± 9.94 mgaml). As evidenced in Table 6 the majority of the non-HPN patients in groups B and C had low plasma a-tocopherol concentrations. Low plasma a-tocopherol concentrations were also demonstrated in the HPN patients in spite of the parenteral supplements of fat soluble vitamins or lipids given to all except eight HPN patients. Three of these eight patients had low plasma a-tocopherol concentrations. The g-tocopherol concentration was signi®-cantly higher in the HPN patients receiving parenteral lipids compared with the controls, the non-HPN patients in groups B and C and the HPN patients in group E (Table  6 ). Thus, none of the HPN patients receiving parenteral lipid had a plasma g-tocopherol concentration below De®ciencies related to fat malabsorption PB Jeppesen et al 0.28 mgaml, which was the lower limit of the 2.5 ± 97.5% con®dence interval in the control subjects. Figure 4 demonstrates a close and signi®cant correlation between plasma total a-tocopherol equivalents and the total cholesterol in plasma.
Discussion
We previously demonstrated that a proportion of patients with severe fat malabsorption have low concentrations of essential fatty acids in plasma (Jeppesen et al, 1997) , which also is encountered in patients receiving HPN (Jeppesen et al, 1998c) . In the present study, which included both non-HPN and HPN patients, identi®cation of the individual fatty acids in the diet and faeces by combined gas ± liquid chromatography and mass spectrometry rendered it possible to measure the absorption of the essential fatty acids, linoleic and linolenic acids, and a correlation between the intestinal absorption of linoleic acid and the concentrations in the plasma phospholipids was demonstrated (Figure 1 ). Essential fatty acid de®ciency (EFAD) is traditionally de®ned as a 20:3n-9a20:4n-6 ratio (Holman index) above 0.2. However, the lack of coherence between clinical Results are expressed as median with 25% and 75% percentiles given in parentheses. FAaTEA fat absorptionatotal energy absorption (%). Total energy supply corresponds to the sum of the intestinal energy absorption and the parenteral energy supply. *Kruskal ± Wallis one-way Anova on ranks. The subscripts a ± d denote statistical difference, P`0.05, by all pairwise multiple comparison procedures (Tukey's test) for multiple comparisons. Total alfa-tocopherol equivalents`4.34 mga ml, n x (%) 1 (3%) 4 (29%) 10 (67%) 11 (73%) 10 (81%) 12 (50%) Ð
Results are expressed as median with 25% and 75% percentiles given in parentheses. FAaTEA fat absorptionatotal energy absorption (%). Total energy supply corresponds to the sum of the intestinal energy absorption and the parenteral energy supply. *Kruskal ± Wallis one-way Anova on ranks. The subscripts a ± d denote statistical difference, P`0.05, by all pairwise multiple comparison procedures (Tukey's test) for multiple comparisons. Total alfatocopherol equivalents is calculated as alfa-tocoherol 0.2 gamma-tocopherol. # The value corresponds to the lower limit of the 2.5% ± 97.5% con®dence interval in control subjects.
De®ciencies related to fat malabsorption PB Jeppesen et al manifestations and this biochemical marker makes a clear demarcation between the de®ciency and suf®ciency state dif®cult, and other fatty acid concentrations and ratios have been proposed as alternative indicators of EFAD (Siguel et al, 1987) . EFAD causes a reduction in some of the essential n-6 and n-3 fatty acids and is often accompanied by an elevation in some of the non-essential n-7 and n-9 fatty acids (Jeppesen et al, 1997) , which was mainly encountered in the numerator of the Holman index, with decreasing concentrations of linoleic acid (Figure 2 and Table 4 ). An omission of the denominator, 20:4n-6, in the Holman index (20:3n-9a20:4n-6) or its replacement by linoleic acid, 18:2n-6, selected the same 10 patients with an index above 0.2, demarcated with bold lines in Figure 3 , whereas the ratio between the total amounts of essential n-6 and n-3 fatty acids and nonessential n-7 and n-9 fatty acids selected differently for some of the patients. The Holman index nominator, 20:3n-9 was only elevated in patients with concentrations of linoleic acid, 18:2n-6, below 10% and 20:3n-9 was not increased in a single non-HPN patient (Figure 2A ). In accordance with the ®ndings of Mascioli et al (1996) , a 20:3n-9 b2% was only encountered in HPNpatients not receiving parenteral lipids (Figure 2A ), who also were the only patients with biochemical signs of EFAD de®ned as a Holman index b0.2, which nevertheless was a very common ®nding in nearly half of the patients from this group (Table 4) . Therefore, patients with very low concentrations of linoleic acid,`10%, are probably candidates to receive treatment with parenteral essential fatty acids (contained in the ordinary products used for parenteral lipid supplementation), especially in the presence of a coexisting secondary rise in 20:3n-9 b2% and the Holman index. This limited strategy would virtually exclude non-HPN patients as candidates (only two had concentrations of linoleic acid`10%), but include the majority of HPN-patients (Figure 2 ). In our view, the clinical signi®cance of an intermediately decreased plasma linoleic acid is uncertain and it is usually not associated with secondary changes in fatty acid composition and an increase in the Holman index. One may argue that half (20 out of 44) of the non-HPN patients in this study should receive parenteral lipids as well, if treatment is guided by a desire to increase plasma linoleic acid above 15%, which still is well below concentrations in healthy controls. However, in non-HPN patient recommended a low-fat diet, as it is conventionally done in patients who malabsorb large quantities of fat, a low plasma linoleic acid 15% may bring speculation about whether such a diet is still optimal and whether dietary fat could include more essential fatty acids.
Jeejeebhoy et al advocated daily lipid infusions of approximately 500 ml of 10% Intralipid in order to prevent a linoleic acid de®ciency of the phospholipids of membranes (Jeejeebhoy et al, 1990b) . The practice in our unit has been to limit parenteral lipids to patients in need of a signi®cant parenteral supply of energy. Patients primarily in need of parenteral saline who only require low energy parenteral nutrition were less frequently supplemented with lipids. Accordingly, the HPN-patients receiving lipids absorbed less energy (3.00 vs 4.31 MJaday, Table 2 ) by the enteral route, and received more energy by the parenteral route (5.74 vs 2.71 MJaday, Table 3 ) compared with patients not supplemented with lipids. Our impression over 30 y of experience has been that this regimen has not caused clinical problems which could be attributed to EFAD. Nevertheless, the results obtained in this study have changed our policy and we now supply lipids to the majority of our HPN population except those only treated with parenteral saline. We still use moderate amounts of lipids, eg 20% intralipids, 500 ml once or twice a week, which seems to be adequate to avoid the increase in the 20:3n-9 fatty acids and a rise in the Holman index. As mentioned, we do not ®nd it suf®ciently justi®ed to aim at a normalization of plasma linoleic acid, which would require a considerable increase in the administered amounts of parenteral lipids compared to our current practice. The fact that linoleic acid in plasma was signi®cantly lower in the HPN patients treated with parenteral lipids in group D in comparison with the non-HPN patients in group A (12.1% vs 17.3%, Table 4) despite the amount of linoleic acid received by the organism was identical (7.5 and 0.5 gaday by the parenteral and enteral route, respectively, in group D and 8.2 gaday by the enteral route in group A, Tables 2 and  3) , may also lend support to the view that the dosage of parenteral linoleic acid has to include other considerations than a moderate reduction in the plasma concentration.
Cholesterol was lowered in both the non-HPN and the HPN patients (Table 5) , probably re¯ecting the reduced intestinal absorption of fat (and cholesterol), the primary determinants of plasma cholesterol and LDL cholesterol levels (Dietschy, 1998) . The resection of the terminal ileum and a corresponding loss of bile acids caused by the interruption the enterohepatic bile acid circulation may also have contributed. LDL cholesterol was low and HDL cholesterol was normal in the non-HPN patients Ð changes also described after intestinal bypass operations for hyperlipidemia (Goldberg et al, 1983; Sorensen et al, 1982; Moore et al, 1980) . LDL and HDL cholesterol were reduced in HPN patients receiving parenteral lipids, as earlier reported by Levy et al (1987) with HDLatotal cholesterol ratios comparable to values in healthy controls (Table 5) .
Vitamin A de®ciency has been described in short bowel patients whether or not parenteral nutrition was required (Gans & Taylor, 1990; Howard et al, 1980) , although Smith & Lindenbaum (1974) found normal mean serum concentrations of vitamin A and retinol-binding-protein (RBP) in 22 adults with a moderate fat malabsorption (22 gaday). It Figure 4 The relationship between total a-tocopherol equivalents (calculated as a-tocopherol 0.2 g-tocopherol) and total cholesterol. (s) Control subjects; (e) patients in group A; (D) patients in group B; (m) patients in group C; (u) patients in group E.
De®ciencies related to fat malabsorption PB Jeppesen et al is suggested that hepatic stores of vitamin A are mobilised when supplies are reduced, and Underwood et al calculated that a drop in the plasma retinol concentration would not be anticipated for up to 220 days in a complete absence of dietary vitamin A (Underwood et al, 1970) . We found that three out of 44 non-HPN-patients (7%) and eight out of 40 HPN-patients (20%) had retinol concentrations below the lower 2.5% con®dence limit found in healthy controls ( Table 6 ), suggesting that sporadic cases of vitamin A de®ciencies may occur especially in patients on HPN, although the median plasma retinol in the HPN-and non-HPN-patients did not differ signi®cantly from concentrations in healthy controls (Table 6 ). Shils et al (1985) found that the AMA-FDA daily dose of 3300 mg maintained most blood vitamin levels within a normal range in HPNpatients, which was con®rmed by Davis et al (1987) . In this study HPN-patients with normal plasma retinol received a median parenteral dose of 141 mgaday (range 0 ± 141 mgaday), which was equivalent to the amount given to the eight HPN-patients with low plasma retinol (median 141 mgaday, range 0 ± 141 mgaday). Thus, the few HPNpatients with low plasma levels of retinol (vitamin A) may be advised to receive increased supplementation according to repeated measurements. Vitamin E de®ciency has also been reported in intestinal disorders with malabsorption (Goransson et al, 1973; Ghalaut et al, 1995) . Vitamin E is mainly located in the adipose tissue in the bulk lipid stores but is not readily mobilized (Traber & Kayden, 1987; Schaefer et al, 1983) . In this study vitamin E was measured as plasma concentrations of a-and g-tochopherol, which may be inappropriate because plasma vitamin E concentrations depend on circulating lipid concentrations (Horwitt et al, 1972) in accordance with the correlation found between a-tocopherol equivalents and cholesterol (Figure 4) . Vitamin E primarily functions as a membrane-bound, chain-breaking antioxidant, and it has been suggested that the tocopherol concentration in membranes of red blood cells may be a better index of vitamin E status (Kelly & Sutton, 1989) . The majority of the HPN-patients and the non-HPN patients with the more severe fat malabsorption had plasma concentrations of a-tocopherol below the lower 2.5% con®-dence limit in healthy controls in spite of parenteral supplementations with 2.6 and 1.3 mgaday in groups D and E, respectively. This is less than the recommended dose of 10 mgaday (Americal Medical Association Department of Food and Nutrition, 1979) , and our ®ndings may support this recommendation and, if so, one may similarly argue that treatment with vitamin E also should be extended to non-HPN patients with severe fat malabsorption. Likewise, a considerable proportion of the patients had g-tochopherol concentrations below the lower limits found in controls (Table 6) , except patients treated with Intralipid, known to contain 6 ± 10 times more g-tochopherol than a-tocopherol due to its content of soybean oil (Gutcher et al, 1984; Vandewoude et al, 1986) .
In conclusion, abnormalities in the fatty acid composition of plasma phospholipids, lipoproteins and of plasma concentrations of vitamins A and E were demonstrated, both in short bowel patients with intestinal failure necessitating parenteral support and in patients with severe fat malabsorption managed without parenteral support. Subclinical damage and unexplained symptoms cannot be excluded as being associated with the various de®ciencies found in these patients, but the clinical signi®cance is not quite clear to us, because cases where we have been able to identify symptoms associated with these biochemical indicators have been extremely rare. Signs of essential fatty acid de®ciencies resulting in an increase in the Holman index were only encountered in HPN-patients not treated with parenteral lipids, which we now recommend is avoided, although we do not aim at a normalization of the plasma linoleic acid concentration. The few, mainly HPN, patients with low plasma levels of retinol (vitamin A) may also be advised to receive increased supplementation, whereas it is unclear if it is necessary to normalize the plasma levels of g-and a-tocopherol (vitamin E), which was low in the majority of the patients.
